Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus li
5 hours ago
- #Induction Chemotherapy
- #Acute Myeloid Leukemia
- #Comparative Analysis
- CPX-351 (liposomal cytarabine and daunorubicin) was previously shown to improve outcomes in t-AML and AML-MRC patients aged 60-75 compared to standard 7+3 induction.
- A post-hoc analysis of t-AML/AML-MRC patients ≥60 years compared higher-intensity 7+3 double-induction (with intermediate-dose cytarabine) to CPX-351 using reconstructed survival data.
- The higher-intensity 7+3 cohort had higher CR/CRi rates (67.8% vs. 47.7%) and similar median OS (10.1 vs. 8.9 months) and safety compared to CPX-351, suggesting comparable efficacy.